NDC-11 (Package) | NDC-9 (Product) (Ascending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67877-0539-07 | 67877-0539 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0539-14 | 67877-0539 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0540-07 | 67877-0540 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0540-14 | 67877-0540 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0541-07 | 67877-0541 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0541-14 | 67877-0541 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0542-07 | 67877-0542 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | April 28, 2017 | In Use | |
67877-0633-90 | 67877-0633 | imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb. 1, 2019 | In Use | |
67877-0634-30 | 67877-0634 | imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb. 1, 2019 | In Use | |
67877-0753-60 | 67877-0753 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
67877-0754-60 | 67877-0754 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
67877-0755-60 | 67877-0755 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
67979-0001-01 | 67979-0001 | Valrubicin | Valstar | 40.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravesical | Oct. 1, 1998 | In Use | |
67979-0001-02 | 67979-0001 | Valrubicin | Valstar | 40.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravesical | Oct. 1, 1998 | Oct. 17, 2017 | In Use |
67979-0500-01 | 67979-0500 | Histrelin Acetate | Vantas | 50.0 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov. 1, 2004 | March 31, 2022 | No Longer Used | |
67979-0501-40 | 67979-0501 | Testosterone Enanthate | DELATESTRYL | 200.0 mg/mL | Hormonal Therapy | Androgen | Intramuscular | Dec. 24, 1953 | Nov. 30, 2014 | No Longer Used | |
68001-0005-01 | 68001-0005 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 2, 2013 | In Use | |
68001-0155-04 | 68001-0155 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 1, 2014 | In Use | ||
68001-0155-08 | 68001-0155 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 1, 2014 | In Use | ||
68001-0246-04 | 68001-0246 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 13, 2018 | In Use | |
68001-0246-16 | 68001-0246 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2014 | In Use | |
68001-0246-17 | 68001-0246 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2014 | In Use | |
68001-0247-01 | 68001-0247 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2014 | Feb. 27, 2018 | In Use |
68001-0247-04 | 68001-0247 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 13, 2018 | In Use | |
68001-0247-16 | 68001-0247 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2014 | In Use |
Found 10,000 results in 9 milliseconds — Export these results